Denali Therapeutics (NASDAQ:DNLI) Given "Buy" Rating at HC Wainwright

Denali Therapeutics (NASDAQ:DNLI - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $90.00 price objective on the stock. HC Wainwright's target price indicates a potential upside of 201.61% from the company's current price.

Several other research firms also recently issued reports on DNLI. JPMorgan Chase & Co. dropped their price objective on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Citigroup upped their price target on Denali Therapeutics from $26.00 to $32.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Jefferies Financial Group lifted their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Friday, November 1st. Wedbush cut their target price on Denali Therapeutics from $30.00 to $26.00 and set an "outperform" rating for the company in a research note on Friday, August 2nd. Finally, Raymond James reaffirmed a "market perform" rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $38.90.

Denali Therapeutics Trading Up 1.0 %

Denali Therapeutics stock traded up $0.29 on Thursday, reaching $29.84. 589,894 shares of the stock were exchanged, compared to its average volume of 1,071,237. The stock has a market cap of $4.27 billion, a PE ratio of -10.37 and a beta of 1.40. The firm has a fifty day moving average price of $27.57 and a two-hundred day moving average price of $23.36. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $32.13.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the company posted ($0.72) earnings per share. Equities analysts anticipate that Denali Therapeutics will post -2.53 EPS for the current fiscal year.

Insider Activity at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 40,000 shares of the business's stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the transaction, the chief executive officer now directly owns 235,807 shares in the company, valued at approximately $6,529,495.83. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the business's stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the transaction, the director now directly owns 29,096 shares of the company's stock, valued at approximately $844,656.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of the stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares of the company's stock, valued at $6,529,495.83. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its holdings in shares of Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company's stock valued at $48,000 after buying an additional 1,847 shares during the period. CWM LLC lifted its position in Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company's stock valued at $63,000 after acquiring an additional 654 shares in the last quarter. Quest Partners LLC acquired a new position in Denali Therapeutics in the 3rd quarter worth $73,000. Assetmark Inc. increased its holdings in Denali Therapeutics by 18.0% during the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company's stock worth $111,000 after purchasing an additional 580 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Denali Therapeutics in the 1st quarter valued at about $88,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.